Ally Bridge Group (NY) LLC - SYROS PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
Ally Bridge Group (NY) LLC ownership history of SYROS PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2022$3,239,000
-19.1%
3,364,8950.0%2.95%
-0.5%
Q1 2022$4,004,000
-65.3%
3,364,895
-4.9%
2.97%
-26.4%
Q4 2021$11,540,000
-24.9%
3,539,895
+2.9%
4.03%
-10.8%
Q3 2021$15,376,000
-18.0%
3,439,8950.0%4.52%
-2.9%
Q2 2021$18,747,000
-20.2%
3,439,895
+9.6%
4.66%
+3.4%
Q1 2021$23,486,000
-18.1%
3,139,895
+18.8%
4.50%
-8.3%
Q4 2020$28,671,0002,642,5004.91%
Other shareholders
SYROS PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 3,139,895$23,486,0004.50%
Samsara BioCapital, LLC 2,189,199$14,769,0002.72%
Bain Capital Life Sciences Investors, LLC 5,785,036$43,272,0002.45%
Omega Fund Management, LLC 1,562,500$11,688,0001.11%
Flagship Pioneering Inc. 2,938,494$21,980,0000.35%
EcoR1 Capital, LLC 1,000,000$7,480,0000.33%
Altium Capital Management LP 126,702$948,0000.26%
Nikko Asset Management Americas, Inc. 5,042,009$37,714,0000.18%
Artal Group S.A. 1,025,000$7,667,0000.14%
Orbimed Advisors 1,837,500$13,745,0000.13%
View complete list of SYROS PHARMACEUTICALS INC shareholders